ADDRESS-2 is supporting a study to assess the safety of a new “type 1 diabetes vaccine” designed to stop the immune system from attacking insulin-producing beta cells.
Research study for people with Type 1 Diabetes: EXALT
Currently recruiting
Summary
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes. The investigational drug is a “therapeutic vaccine” and affects the body’s immune system response to a medical condition or disease. It is designed to stop the immune system from attacking cells that produce insulin, which may help insulin production in patients with recently diagnosed type 1 diabetes.
To pre-qualify for this study, you must:
- Be 18 to 30 years of age
- Have been diagnosed with type 1 diabetes in the last 6 months
- Have an insulin requirement
To find out more contact us
Read about other studies we are supporting.